Small animal PET/CT

我们请求DFG资助molecular小动物PET/CT （ß- and X-Cube组合，“台式PET CT集成平台”），这是一种小型实验室分子成像设备，每个组件分别用于PET和CT。我们的研究重点是转化治疗，基于小放射配体诊断和治疗癌症。转化研究的目的是：前列腺癌是全球男性癌症相关死亡的主要原因之一。我们建立了高表达PSMA的前列腺癌小鼠模型。小动物PET/CT将用于评估示踪剂在小鼠中的替代应用途径。我们进一步的目的是评估VE-822和恩杂鲁胺联合放射配体药物治疗的疗效。成纤维细胞激活蛋白（FAP）在成纤维细胞相关的恶性肿瘤中高水平表达。基于胆碱的放射性标记FAP抑制剂（FAPI）可用于使用正电子发射断层扫描（PET）准确评估乳腺癌，胰腺癌或耳鼻喉肿瘤的程度。我们将开发人类癌症的小鼠模型，以测试各种放射性标记的fap抑制剂的生物分布和准确性。与其他大学机构合作，我们将使用小动物PET/CT成像来评估免疫刺激磷酸钙纳米颗粒，肺癌的虚拟模型，小鼠黑色素瘤模型，以及质子束治疗的离线剂量评估。

We request DFG funding for a Molecubes small animal PET/CT (ß- und X-Cube combination, "benchtop PET CT integrated platform"), a small labspace molecular imaging device with each one component for PET and CT.Our research is focused on translational theranostics, based on small radioligands for diagnosis and treatment of cancer. Translational research aims at: Prostate cancer is one of the leading causes of cancer-related death among men worldwide. We developed a mouse model of prostate cancer with high expression levels of PSMA. Small animal PET/CT will be used to assess alternative routes of tracer application in mice. We further aim to evaluate improved efficacy through radioligand drug combination therapy with VE-822 and Enzalutamide. Fibroblast activation protein (FAP) is expressed at high levels in fibroblast-associated malignancies. Chinolin-based radiolabeled inhibitors of FAP (FAPI) can be applied to accurately assess extent of breast cancer, pancreatic cancer, or ENT tumors using positron-emission-tomography (PET). We will develop a mouse model of human cancer to test various radiolabeled FAP-inhibitors for their biodistribution and accuracy. In collaboration with other University institutions, we will use small animal PET/CT imaging to assess immunstimulatory calciumphosphate nanoparticles, avatar-models of lung cancer, murine melanoma models, and off-line dose assessments for proton beam therapy.